...
首页> 外文期刊>Journal of nephrology. >Continuous renal replacement therapies: anticoagulation in the critically ill at high risk of bleeding.
【24h】

Continuous renal replacement therapies: anticoagulation in the critically ill at high risk of bleeding.

机译:连续性肾脏替代疗法:危重病患者处于高出血风险的抗凝治疗。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND: The ongoing necessity for systemic heparinization is a well-known disadvantage of continuous renal replacement therapies (CRRT), and alternative methods of anticoagulation may be required. Our aim was to evaluate, in patients with a high risk of bleeding, the possibility of an acceptable filter life with non-anticoagulation CRRT and, in case of early filter failure, the efficacy and safety of bedside monitored regional anticoagulation with heparin and protamine. METHODS: Fifty-nine patients underwent CRRT for acute renal failure (ARF) following cardiac surgery. Patients who fulfilled one of the following criteria were selected for non-anticoagulation CRRT: spontaneous bleeding, aPTT > 45 sec, thrombocytopenia and recent surgery (< 48 hr). Filter life < 24 hr without anticoagulation was the cut-off point for starting the regional anticoagulation CRRT. Heparin was infused pre-filter and protamine post-filter at an initial ratio of 1 mg protamine:100 IU heparin. The ratio was adjusted to achieve a patient aPTT < 45 sec and a circuit > 55 sec. RESULTS: Twenty-two (37.3%) patients had been selected for non-anticoagulation. Of them, 12 patients continued to receive non-anticoagulation (filter life: 38.3 +/- 30.5 hr) while 10 switched to regional anticoagulation (filter life: 38.6 +/- 25 hr). During regional anticoagulation no statistical difference was found between baseline aPTT (36.7 +/- 6.4 sec) and patient aPTT (41.5 +/- 12.6 sec) while circuit aPTT (77.7 +/- 43.3 sec) was significantly higher than patient aPTT (p < 0.0001). The probabilities of the circuits remaining free from clotting after 24, 48 and 72 hr were: a) non-anticoagulation: 55.5%, 30.1% and 16.6%, b) regional anticoagulation: 76.2%, 39.6% and 19.8%. There was no rebound anticoagulation observed after regional anticoagulation CRRT ended. CONCLUSIONS: Non-anticoagulation CRRT allowed an adequate filter life in most patients with a high risk of bleeding for prolonged aPTT and/or thrombocytopenia. Despite concerns regarding the need for careful monitoring, regional anticoagulation with heparin and protamine can be considered as a safe and valid alternative when non-anticoagulation is unsuitable because of early filter failure.
机译:背景:持续进行全身性肝素化的必要性是连续性肾脏替代疗法(CRRT)的众所周知的缺点,可能需要其他抗凝方法。我们的目的是评估出血风险高的患者,使用非抗凝CRRT可以达到可接受的滤器寿命,如果早期滤器出现故障,则可以在床旁监测使用肝素和鱼精蛋白进行局部抗凝的有效性和安全性。方法:59例心脏手术后因急性肾衰竭(ARF)接受CRRT的患者。选择满足以下标准之一的患者进行非抗凝CRRT:自发性出血,aPTT> 45秒,血小板减少和近期手术(<48小时)。在不进行抗凝作用的情况下,<24小时的过滤器寿命是开始局部抗凝CRRT的临界点。肝素以1 mg鱼精蛋白:100 IU肝素的初始比例注入预过滤器和鱼精蛋白后过滤器中。调整比率以实现患者aPTT <45秒和回路> 55秒。结果:选择了22例(37.3%)患者进行非抗凝治疗。其中12例患者继续接受非抗凝治疗(滤池寿命:38.3 +/- 30.5 hr),而10例患者改用局部抗凝治疗(滤池寿命:38.6 +/- 25 hr)。在区域抗凝治疗期间,基线aPTT(36.7 +/- 6.4秒)与患者aPTT(41.5 +/- 12.6秒)之间未发现统计学差异,而回路aPTT(77.7 +/- 43.3秒)明显高于患者aPTT(p < 0.0001)。在24、48和72小时后,回路仍保持不凝结的概率为:a)非抗凝:55.5%,30.1%和16.6%,b)区域抗凝:76.2%,39.6%和19.8%。局部抗凝CRRT结束后未观察到反弹抗凝。结论:非抗凝CRRT在大多数因长期aPTT和/或血小板减少而出血的高风险患者中具有足够的滤器寿命。尽管担心需要进行仔细的监测,但是当由于早期过滤器故障而导致不适合进行非抗凝治疗时,可以使用肝素和鱼精蛋白进行局部抗凝治疗是一种安全有效的选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号